argenx announces intention to conduct a registered public offering in the United States
March 01, 2017 13:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent, Belgium...
argenx to Present at Cowen & Co 37th Annual Health Care conference
February 28, 2017 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent, Belgium-...
argenx announces extension of therapeutic antibody alliance with Shire
February 27, 2017 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent, Belgium...
argenx to Present at Leerink Partners 6th Annual Global Healthcare Conference
February 09, 2017 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent, Belgium-...
argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis
January 09, 2017 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
- Topline data from the study...
argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine
December 29, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent, Belgium...
argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients
December 15, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent,...
argenx to provide updates on ARGX-113 and ARGX-110 during American Society of Hematology Annual Meeting
December 02, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Workshop to occur on Sunday December 4th...
argenx to Present at Upcoming Investor Conferences
November 08, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent,...
argenx Reports Third Quarter 2016 Financial Results and Provides Business Update
October 27, 2016 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Breda, the Netherlands / Ghent,...